Chung-Han Lee1, Robert J Motzer2, Hilary Glen3, M D Michaelson4, James Larkin5, Yukinori Minoshima6, Michio Kanekiyo7, Hiroki Ikezawa8, Pallavi Sachdev7, Corina E Dutcus7, Yasuhiro Funahashi6, Martin H Voss2. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. leec4@mskcc.org. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Medical Oncology, Beatson West of Scotland Cancer Center, Glasgow, UK. 4. Massachusetts General Hospital Cancer Center, Boston, MA, USA. 5. Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK. 6. Eisai Co., Ltd, Ibaraki, Japan. 7. Eisai Inc., Woodcliff Lake, NJ, USA. 8. Eisai, Co., Ltd, Tokyo, Japan.
Abstract
BACKGROUND: No biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores (CBSs) to predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic RCC randomised to receivelenvatinib-plus-everolimus. METHODS: Of 40 biomarkers tested, the 5 most strongly associated with PFS (HGF, MIG, IL-18BP, IL-18, ANG-2) or OS (TIMP-1, M-CSF, IL-18BP, ANG-2, VEGF) were used to make a 5-factor PFS-CBS or OS-CBS, respectively. A 2-factor CBS was generated with biomarkers common to PFS-CBS and OS-CBS. Patients were divided into groups accordingly (5-factor-CBS high: 3-5, CBS-low: 0-2; 2-factor-CBS high: 1-2, CBS-low: 0). RESULTS:PFS/OS with lenvatinib-plus-everolimus were significantly longer in the 5-factor CBS-high group versus the CBS-low group (P = 0.0022/P < 0.0001, respectively). In the CBS-high group, PFS/OS were significantly longer with lenvatinib-plus-everolimus versus everolimus (P < 0.001/P = 0.0079, respectively); PFS was also significantly longer with lenvatinib-plus-everolimus versus lenvatinib (P = 0.0046). The 5-factor-CBS had a predictive role in PFS and OS after multivariate analysis. Similar trends were observed with the 2-factor-CBS for PFS (i.e., lenvatinib-plus-everolimus versus everolimus). CONCLUSIONS: The 5-factor CBS may identify patients with metastatic RCC who would benefit from lenvatinib-plus-everolimus versus everolimus; additional validation is required. CLINICAL TRIAL REGISTRATION: The clinical trial registration number is NCT01136733.
RCT Entities:
BACKGROUND: No biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores (CBSs) to predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic RCC randomised to receive lenvatinib-plus-everolimus. METHODS: Of 40 biomarkers tested, the 5 most strongly associated with PFS (HGF, MIG, IL-18BP, IL-18, ANG-2) or OS (TIMP-1, M-CSF, IL-18BP, ANG-2, VEGF) were used to make a 5-factor PFS-CBS or OS-CBS, respectively. A 2-factor CBS was generated with biomarkers common to PFS-CBS and OS-CBS. Patients were divided into groups accordingly (5-factor-CBS high: 3-5, CBS-low: 0-2; 2-factor-CBS high: 1-2, CBS-low: 0). RESULTS: PFS/OS with lenvatinib-plus-everolimus were significantly longer in the 5-factor CBS-high group versus the CBS-low group (P = 0.0022/P < 0.0001, respectively). In the CBS-high group, PFS/OS were significantly longer with lenvatinib-plus-everolimus versus everolimus (P < 0.001/P = 0.0079, respectively); PFS was also significantly longer with lenvatinib-plus-everolimus versus lenvatinib (P = 0.0046). The 5-factor-CBS had a predictive role in PFS and OS after multivariate analysis. Similar trends were observed with the 2-factor-CBS for PFS (i.e., lenvatinib-plus-everolimus versus everolimus). CONCLUSIONS: The 5-factor CBS may identify patients with metastatic RCC who would benefit from lenvatinib-plus-everolimus versus everolimus; additional validation is required. CLINICAL TRIAL REGISTRATION: The clinical trial registration number is NCT01136733.
Authors: Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar Journal: J Clin Oncol Date: 2004-02-01 Impact factor: 44.544
Authors: Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544
Authors: Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: Samra Turajlic; Hang Xu; Kevin Litchfield; Andrew Rowan; Stuart Horswell; Tim Chambers; Tim O'Brien; Jose I Lopez; Thomas B K Watkins; David Nicol; Mark Stares; Ben Challacombe; Steve Hazell; Ashish Chandra; Thomas J Mitchell; Lewis Au; Claudia Eichler-Jonsson; Faiz Jabbar; Aspasia Soultati; Simon Chowdhury; Sarah Rudman; Joanna Lynch; Archana Fernando; Gordon Stamp; Emma Nye; Aengus Stewart; Wei Xing; Jonathan C Smith; Mickael Escudero; Adam Huffman; Nik Matthews; Greg Elgar; Ben Phillimore; Marta Costa; Sharmin Begum; Sophia Ward; Max Salm; Stefan Boeing; Rosalie Fisher; Lavinia Spain; Carolina Navas; Eva Grönroos; Sebastijan Hobor; Sarkhara Sharma; Ismaeel Aurangzeb; Sharanpreet Lall; Alexander Polson; Mary Varia; Catherine Horsfield; Nicos Fotiadis; Lisa Pickering; Roland F Schwarz; Bruno Silva; Javier Herrero; Nick M Luscombe; Mariam Jamal-Hanjani; Rachel Rosenthal; Nicolai J Birkbak; Gareth A Wilson; Orsolya Pipek; Dezso Ribli; Marcin Krzystanek; Istvan Csabai; Zoltan Szallasi; Martin Gore; Nicholas McGranahan; Peter Van Loo; Peter Campbell; James Larkin; Charles Swanton Journal: Cell Date: 2018-04-12 Impact factor: 41.582
Authors: Maria E Cabanillas; Martin Schlumberger; Barbara Jarzab; Renato G Martins; Furio Pacini; Bruce Robinson; Judith C McCaffrey; Manisha H Shah; Donald L Bodenner; Duncan Topliss; Corina Andresen; James P O'Brien; Min Ren; Yasuhiro Funahashi; Roger Allison; Rossella Elisei; Kate Newbold; Lisa F Licitra; Steven I Sherman; Douglas W Ball Journal: Cancer Date: 2015-04-24 Impact factor: 6.860
Authors: Petra Ross-Macdonald; Alice M Walsh; Scott D Chasalow; Ron Ammar; Simon Papillon-Cavanagh; Peter M Szabo; Toni K Choueiri; Mario Sznol; Megan Wind-Rotolo Journal: J Immunother Cancer Date: 2021-03 Impact factor: 13.751
Authors: Philip Zeuschner; Sebastian Hölters; Michael Stöckle; Barbara Seliger; Anja Mueller; Hagen S Bachmann; Viktor Grünwald; Daniel C Christoph; Arnulf Stenzl; Marc-Oliver Grimm; Fabian Brüning; Peter J Goebell; Marinela Augustin; Frederik Roos; Johanna Harde; Iris Benz-Rüd; Michael Staehler; Kerstin Junker Journal: Cancers (Basel) Date: 2021-05-25 Impact factor: 6.639